Researchers at Lund University in Sweden have compared the effects of intravenous ketamine treatment with ECT (electroconvulsive therapy) treatment in severe depression. The results support the view that ketamine is a possible ...
Jan 11, 2022
0
118
About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as patches of red, inflamed skin and painful, scaly rashes. Although there are effective treatments for psoriasis, not everyone responds ...
Nov 19, 2021
0
61
A clinical trial has found people prefer receiving information on the 5:2 diet than standard GP weight management advice despite both interventions achieving similar modest weight loss results.
Nov 17, 2021
0
17
A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, ...
Nov 11, 2021
0
11
On Nov. 2, the Centers for Disease Control and Prevention recommended that COVID-19 vaccinations be given to children as young as 5. Pediatricians' offices, pharmacies and health systems are preparing to offer the Pfizer-BioNTech ...
Nov 9, 2021
0
3
Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, according to a new study ...
Oct 27, 2021
0
29
Bronchial asthma causes symptoms such as wheezing and cough due to chronic airway inflammation, but there is no fundamental treatment for it, leaving a desire for new prevention and treatment methods. Now a new study reveals ...
Oct 26, 2021
0
1
A new national report released today highlights a decline in hepatitis C testing and treatment uptake, putting Australia at risk of not achieving its target of eliminating hepatitis C as a public health threat by 2030.
Oct 25, 2021
0
4
The Australian government has pre-purchased 300,000 courses of an experimental antiviral oral drug called molnupiravir.
Oct 6, 2021
0
6
The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo. The late breaking results of the KEYNOTE-716 trial are presented ...
Sep 20, 2021
0
4
